<html>
<head>PUBMED IDs for RGC-32</head>
<body bgcolor='#C5F0F2'><h1>RGC-32</h1><a href='https://pubmed.ncbi.nlm.nih.gov/9756947/'>Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes.</a> October 3  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/15591621/'>The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription.</a> December 14  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/15713436/'>Overexpression of RGC-32 in colon cancer and other tumors.</a> February 17  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/18373239/'>Role of response gene to complement 32 in diseases.</a> April 1  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/18373191/'>Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.</a> April 1  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/19158077/'>RGC-32 mediates transforming growth factor-beta-induced epithelial-mesenchymal transition in human renal proximal tubular cells.</a> June 2  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19158075/'>Differential gene expression in vertebrate embryos.</a> July 1  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19158050/'>Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.</a> April 11  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19158046/'>Discovery of a human peptide sequence signaling islet neogenesis.</a> April 11  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19162005/'>Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.</a> April 16  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19883641/'>Epigenetic modifications induced by RGC-32 in colon cancer.</a> February 26  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/21307346/'>Response gene to complement 32 interacts with Smad3 to promote epithelial-mesenchymal transition of human renal tubular cells.</a> August 30  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21850539/'>Membrane attack by complement: the assembly and biology of terminal complement complexes.</a> January 20  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21990365/'>Response gene to complement 32 is essential for fibroblast activation in renal fibrosis.</a> January 24  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22163048/'>Upregulation of the cell-cycle regulator RGC-32 in Epstein-Barr virus-immortalized cells.</a> July 21  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/23000427/'>Dual role of Response gene to complement-32 in multiple sclerosis.</a> April 4  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23247987/'>Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.</a> December 16  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23247927/'>Predictors of haemoconcentration at delivery: association with low birth weight.</a> April 25  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24397908/'>SIRT1 is decreased during relapses in patients with multiple sclerosis.</a> May 29  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/24973210/'>Response gene to complement 32 protein promotes macrophage phagocytosis via activation of protein kinase C pathway.</a> December 17  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25230890/'>C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation.</a> June 30  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25418473/'>Response gene to complement 32 (RGC-32) expression on M2-polarized and tumor-associated macrophages is M-CSF-dependent and enhanced by tumor-derived IL-4.</a> August 10  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25418471/'>Altering macrophage polarization in the tumor environment: the role of response gene to complement 32.</a> August 11  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26407760/'>RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.</a> April 23  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/27619159/'>RGC-32 is expressed in the human atherosclerotic arterial wall: Role in C5b-9-induced cell proliferation and migration.</a> September 14  2016<br></body></html>
